Cell Therapeutics Pays Up In Off-Label Marketing Case
Cell Therapeutics Inc. has agreed to shell out $10.5 million to resolve claims that it promoted its leukemia treatment for uses not cleared first with the U.S. Food and Drug Administration....To view the full article, register now.
Already a subscriber? Click here to view full article